These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection. Mitsuya H J Enzyme Inhib; 1992; 6(1):1-8. PubMed ID: 1285300 [No Abstract] [Full Text] [Related]
24. A formulation for correlating properties of peptides and its application to predicting human immunodeficiency virus protease-cleavable sites in proteins. Chou JJ Biopolymers; 1993 Sep; 33(9):1405-14. PubMed ID: 8400033 [TBL] [Abstract][Full Text] [Related]
25. Mechanical effects on the kinetics of the HIV proteinase deactivation. Kuzmic P; Peranteau AG; García-Echeverría G; Rich DH Biochem Biophys Res Commun; 1996 Apr; 221(2):313-7. PubMed ID: 8619852 [TBL] [Abstract][Full Text] [Related]
26. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
27. The HIV-1 protease as a therapeutic target for AIDS. Debouck C AIDS Res Hum Retroviruses; 1992 Feb; 8(2):153-64. PubMed ID: 1540403 [TBL] [Abstract][Full Text] [Related]
28. Closing in on human immunodeficiency virus-1. Mellors JW Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219 [No Abstract] [Full Text] [Related]
29. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis. Culberson JC; Bush BL; Sardana VV Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190 [No Abstract] [Full Text] [Related]
30. Recent advances in the design of HIV proteinase inhibitors. Martin JA Antiviral Res; 1992 Apr; 17(4):265-78. PubMed ID: 1642479 [TBL] [Abstract][Full Text] [Related]
31. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406 [TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus proteinase: now, then, what's next? Graves MC Adv Exp Med Biol; 1991; 306():395-405. PubMed ID: 1812736 [No Abstract] [Full Text] [Related]
35. Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences. Sakurai M; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y Chem Pharm Bull (Tokyo); 1993 Aug; 41(8):1369-77. PubMed ID: 8403085 [TBL] [Abstract][Full Text] [Related]
36. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state]. Kiso Y Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066 [No Abstract] [Full Text] [Related]
37. Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. Neurath AR; Lin K; Strick N; Jiang S AIDS Res Hum Retroviruses; 1995 Feb; 11(2):189-90. PubMed ID: 7742033 [No Abstract] [Full Text] [Related]